Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 158

Similar articles for PubMed (Select 22649123)

1.

The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus.

Lafeber M, Grobbee DE, Spiering W, van der Graaf Y, Bots ML, Visseren FL; SMART Study Group.

Eur J Prev Cardiol. 2013 Oct;20(5):771-8. doi: 10.1177/2047487312449587. Epub 2012 May 30.

PMID:
22649123
2.

The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease.

Lafeber M, Spiering W, van der Graaf Y, Nathoe H, Bots ML, Grobbee DE, Visseren FL.

Am Heart J. 2013 Aug;166(2):282-289.e1. doi: 10.1016/j.ahj.2013.04.011. Epub 2013 Jun 15.

PMID:
23895811
3.

Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe.

Thom S, Field J, Poulter N, Patel A, Prabhakaran D, Stanton A, Grobbee DE, Bots ML, Reddy KS, Cidambi R, Rodgers A.

Eur J Prev Cardiol. 2014 Feb;21(2):252-61. doi: 10.1177/2047487312463278. Epub 2012 Oct 4.

PMID:
23038750
4.

Predicting the impact of polypill use in a metabolic syndrome population: an effectiveness and cost-effectiveness analysis.

Zomer E, Owen A, Magliano DJ, Ademi Z, Reid CM, Liew D.

Am J Cardiovasc Drugs. 2013 Apr;13(2):121-8. doi: 10.1007/s40256-013-0019-2.

PMID:
23532687
5.

[The Polypill: between myths and reality in the treatment of type 2 diabetes mellitus].

Ruiz J, Egli M.

Rev Med Suisse. 2006 May 31;2(68):1480-2, 1484-5. Review. French.

PMID:
16783994
6.

The evening versus morning polypill utilization study: the TEMPUS rationale and design.

Lafeber M, Grobbee DE, Bots ML, Thom S, Webster R, Rodgers A, Visseren FL, Spiering W.

Eur J Prev Cardiol. 2014 Apr;21(4):425-33. doi: 10.1177/2047487313476961. Epub 2013 Feb 4.

PMID:
23382539
7.

Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.

Indian Polycap Study (TIPS), Yusuf S, Pais P, Afzal R, Xavier D, Teo K, Eikelboom J, Sigamani A, Mohan V, Gupta R, Thomas N.

Lancet. 2009 Apr 18;373(9672):1341-51. doi: 10.1016/S0140-6736(09)60611-5. Epub 2009 Mar 30.

PMID:
19339045
8.
9.

Is a statin as part of a polypill the answer?

Robinson JG.

Curr Atheroscler Rep. 2009 Jan;11(1):15-22. Review.

PMID:
19080723
10.

Changes in preventive medical therapies and CV risk factors after CT angiography.

Cheezum MK, Hulten EA, Smith RM, Taylor AJ, Kircher J, Surry L, York M, Villines TC.

JACC Cardiovasc Imaging. 2013 May;6(5):574-81. doi: 10.1016/j.jcmg.2012.11.016. Epub 2013 Apr 10.

11.

Could the polypill improve adherence? The patient perspective.

Bryant L, Martini N, Chan J, Chang L, Marmoush A, Robinson B, Yu K, Wong M.

J Prim Health Care. 2013 Mar 1;5(1):28-35.

PMID:
23457692
12.

The cardiovascular polypill in high-risk patients.

Lafeber M, Spiering W, Singh K, Guggilla RK, Patil V, Webster R; SPACE collaboration.

Eur J Prev Cardiol. 2012 Dec;19(6):1234-42. doi: 10.1177/1741826711428066. Epub 2011 Oct 21. Review.

PMID:
22019908
13.

[Cardiovascular polypill in high risk patients].

Lafeber M, Spiering W, Bots ML, de Valk V, Visseren FL, Grobbee DE.

Ned Tijdschr Geneeskd. 2011;155(44):A3070. Review. Dutch.

PMID:
22067559
14.

A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization.

Soliman EZ, Mendis S, Dissanayake WP, Somasundaram NP, Gunaratne PS, Jayasingne IK, Furberg CD.

Trials. 2011 Jan 5;12:3. doi: 10.1186/1745-6215-12-3.

15.

Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease.

Blinc A, Poredos P.

Eur J Clin Invest. 2007 Mar;37(3):157-64. Review.

PMID:
17359482
16.

Should we prescribe statin and aspirin for every diabetic patient? Is it time for a polypill?

Wienbergen H, Senges J, Gitt AK.

Diabetes Care. 2008 Feb;31 Suppl 2:S222-5. doi: 10.2337/dc08-s253. No abstract available.

PMID:
18227489
17.

Lipid lowering targets are easier to attain than those for treatment of hypertension in type 2 diabetes.

Sherlock M, Mylotte D, Mac Mahon J, Moore KB, Thompson CJ.

Ir J Med Sci. 2006 Oct-Dec;175(4):36-41.

PMID:
17312827
18.

A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.

Carey KM, Comee MR, Donovan JL, Kanaan AO.

Ann Pharmacother. 2012 May;46(5):688-95. doi: 10.1345/aph.1Q621. Epub 2012 May 8. Review.

PMID:
22570437
19.

Cardiovascular disease prevention using fixed dose pharmacotherapy in Iran: updated meta-analyses and mortality estimation.

Sepanlou SG, Farzadfar F, Jafari E, Danaei G.

Arch Iran Med. 2012 Sep;15(9):531-7. doi: 012159/AIM.004. Review.

20.

Applying the evidence: do patients with stroke, coronary artery disease, or both achieve similar treatment goals?

Saposnik G, Goodman SG, Leiter LA, Yan RT, Fitchett DH, Bayer NH, Casanova A, Langer A, Yan AT; Vascular Protection; Guidelines-Oriented Approach to Lipid-Lowering Registries Investigators; Stroke Outcome Research Canada Working Group.

Stroke. 2009 Apr;40(4):1417-24. doi: 10.1161/STROKEAHA.108.533018. Epub 2009 Feb 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk